---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-038385"
form_type: "8-K"
ticker: "ENVB"
cik: "0000890821"
company_name: "Enveric Biosciences, Inc."
filed_at: "2026-08-14T20:15:54+00:00"
generated_at: "2026-08-14T20:24:27.743397+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Enveric Biosciences Q2 2026 net loss $3.0M, cash $8.3M, EB-003 IND studies advance

## Summary
- Net loss $3.0M ($0.76/share) vs $2.5M ($11.65/share) in Q2 2025; cash $8.3M at June 30, 2026.
- Raised $5.0M gross from private placement plus $1.5M from warrant exercises during Q2.
- Advanced EB-003 IND-enabling studies: genotoxicity initiated, non-hallucinogenic GloSensor data, no photoreactivity.
- Secured U.S. Patent 12,605,361 for EVM301 series; received USPTO Notice of Allowance for EVM401 series.
- Plans IND submission and Phase 1 trial for EB-003 in H2 2026.

## SEC filing metadata
- accession: 0001493152-26-038385
- form_type: 8-K
- ticker: ENVB
- cik: 0000890821
- company_name: Enveric Biosciences, Inc.
- filed_at: 2026-08-14T20:15:54+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/890821/000149315226038385/0001493152-26-038385-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/890821/000149315226038385/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-038385
- JSON: https://secwatch.observer/filing/0001493152-26-038385.json
- Plain text: https://secwatch.observer/filing/0001493152-26-038385.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.